A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)

被引：0
|
作者：
Advani, Anjali S. [1 ]
Sobecks, Ronald [1 ]
Sekeres, Mikkael A. [1 ]
Copelan, Ed [1 ]
Bates, Jennifer [1 ]
Tripp, Barbara [1 ]
Salvado, August [2 ]
Kalaycio, Matt [1 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.906.906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
906
引用
收藏
页码：276A / 276A
页数：1
相关论文
共 50 条
  • [1] A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
    Advani, Anjali S.
    Tiu, Ramon
    Saunthararajah, Yogen
    Maciejewski, Jaroslaw
    Copelan, Edward A.
    Sobecks, Ronald
    Sekeres, Mikkael A.
    Bates, Jennifer
    Rush, Mary Lynn
    Tripp, Barbara
    Salvado, August
    Noon, Elysa
    Howard, Matthew
    Jin, Tao
    Hsi, Eric
    Egorin, Merrill J.
    Lim, Kathleen
    Cotta, Claudiu V.
    Price, Courtney
    Kalaycio, Matt
    LEUKEMIA RESEARCH, 2010, 34 (12) : 1622 - 1626
  • [2] A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.
    Advani, Anjali
    Copelan, Edward A.
    Sobecks, Ronald
    Sekeres, Mikkael A.
    Bates, Jennifer
    Rush, Mary Lynn
    Tripp, Barbara
    Noon, Elysa
    Howard, Matthew
    Jin, Tao
    Hsi, Eric
    Kalaycio, Matt
    BLOOD, 2008, 112 (11) : 351 - 352
  • [3] A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)
    Advani, Anjali
    Cooper, Brenda
    Sowunmi, Olumuyiwa
    Elson, Paul
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu
    Sekeres, Mikkael A.
    Kalaycio, Matt
    Sobecks, Ronald
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Davis, Randall
    Bailey, Laura
    Foster, Bethany
    Rush, Mary Lynn
    Adams, Donna
    Tse, William
    BLOOD, 2012, 120 (21)
  • [4] A phase II pilot study of Gleevec/Glivec (imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML).
    Fischer, T
    Beck, J
    Duyster, J
    Peschel, C
    Müller-Navia, J
    Jäger, E
    Knuth, A
    Gschaidmeier, H
    Huber, C
    BLOOD, 2002, 100 (11) : 561A - 561A
  • [5] Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Tse, William
    Jia, Xuefei
    Elson, Paul
    Cooper, Brenda
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati V.
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu V.
    Kalaycio, Matt
    Sobecks, Ronald M.
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Fensterl, Jaime
    Bailey, Laura
    Carew, Jennifer S.
    Foster, Bethany
    Rush, Mary Lynn
    Adams, Donna
    Griffiths, Elizabeth A.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [6] Response to high dose (HD) imatinib therapy in relapsed c-kit plus acute myeloid leukemia (AML).
    Buda, EM
    Van Echo, DC
    Weiss, B
    Cruser, DL
    Alvarez, GV
    Reid, TJ
    BLOOD, 2004, 104 (11) : 216B - 217B
  • [7] A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia
    Advani, Anjali S.
    Tse, William
    Li, Hong
    Jia, Xuefei
    Elson, Paul
    Cooper, Brenda
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati, V
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu, V
    Kalaycio, Matt
    Sobecks, Ronald M.
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Fensterl, Jaime
    Carew, Jennifer S.
    Foster, Bethany
    Rush, Mary Lynn
    Tripp, Barbara
    Adams, Donna
    Corrigan, Donna
    Griffiths, Elizabeth A.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02): : 113 - 118
  • [8] The efficacy and safety of imatinib in adult patients with C-Kit positive acute myeloid leukemia.
    Kindler, T
    Breitenbuecher, F
    Marx, A
    Beck, J
    Hess, G
    Weinkauf, B
    Duyster, J
    Peschel, C
    Kirkpatrick, CJ
    Theobald, M
    Gschaidmeier, H
    Huber, C
    Fischer, T
    BLOOD, 2003, 102 (11) : 871A - 871A
  • [9] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
  • [10] Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia:: is this the real target?
    Malagola, M
    Martinelli, G
    Rondoni, M
    Paolini, S
    Gaitani, S
    Arpinati, M
    Piccaluga, PP
    Amabile, M
    Basi, C
    Ottaviani, E
    Candoni, A
    Gottardi, E
    Cilloni, D
    Bocchia, M
    Saglio, G
    Lauria, F
    Fanin, R
    Visani, G
    Marré, MC
    Maderna, M
    Rancati, F
    Vinaccia, V
    Russo, D
    Baccarani, M
    BLOOD, 2005, 105 (02) : 904 - 904
12345